Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPHDrug Manufacturers - Specialty & Generic
-$0.31 today
- Market cap
- $1.27B
- Beta
- 0.90
- P/E (TTM)
- 10.9
- EPS (TTM)
- $1.75
Volume 0.53M
Average 0.59M
AMPH Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $4.55M (cash outflow) fell 43.7% year over year, ahead of the -56.6% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -14.3% a year.
Context
- Accounts receivables amounted to 0.9% of revenue in FY2025, down 2.1 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -43.7% holds above the trailing-twelve-month pace of -56.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (6.37M) USD
- Year-over-year change
- +70.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.37M) | +70.6% |
| FY2024 | 2024-12-31 | (21.67M) | +16.9% |
| FY2023 | 2023-12-31 | (26.09M) | -157.5% |
| FY2022 | 2022-12-31 | (10.13M) | +32.1% |
| FY2021 | 2021-12-31 | (14.92M) | — |
Accounts Receivables vs competitors
How AMPH compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -56.6% is the 5th highest of 7, against a peer median of +64.6%.
- Accounts receivables amounts to 0.4% of revenue for AMPH, versus a peer median of 0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹1.39B INR | +110.1% | +7.1% | 0.4% | |
| LTM Jun 2026 | $212.6M USD | +439.5% | +15.1% | 6.8% | |
| LTM Jun 2026 | $76.6M USD | -118.0% | — | 0.5% | |
| LTM Jun 2026 | $73.72M USD | +19.1% | +33.7% | 0.7% | |
| LTM Mar 2026 | $2.99M USD | +122.4% | — | 3.4% | |
| LTM Mar 2026 | $2.84M USD | -56.6% | -14.3% | 0.4% | |
| LTM Mar 2026 | $60K USD | -99.4% | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding AMPH) | — | +64.6% | +15.1% | 0.5% | |
Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 63.3M | 91.39M | 137.55M | 159.52M | 98.09M |
| Depreciation & Amortization | 26.75M | 28.74M | 41.78M | 57.21M | 63.2M |
| Deferred Income Tax | 4.21M | (15.75M) | (13.74M) | (17.87M) | 27.63M |
| Stock-Based Compensation | 18.69M | 17.86M | 20.24M | 24.37M | 27.28M |
| Change in Working Capital | (1.92M) | (32.18M) | (24.21M) | (14.55M) | (65.97M) |
| Accounts Receivables | (14.92M) | (10.13M) | (26.09M) | (21.67M) | (6.37M) |
| Inventory | 1.26M | (11.75M) | (1.72M) | (48.8M) | (21.06M) |
| Accounts Payables | 3.02M | (736K) | 13.24M | 63.56M | (4.56M) |
| Other Working Capital | 8.72M | (9.56M) | (9.64M) | (7.64M) | (33.98M) |
| Other Non-Cash Items | (13.03M) | (878K) | 21.89M | 4.71M | 5.89M |
| Operating Cash Flow | 97.99M | 89.18M | 183.5M | 213.39M | 156.12M |
| Capital Expenditures | (27.46M) | (24.03M) | (38.17M) | (41.04M) | (34.88M) |
| Acquisitions (Net) | 0 | 421K | (506.41M) | (129M) | 0 |
| Purchases of Investments | (17.38M) | (35.76M) | (144.56M) | (76.79M) | (119.13M) |
| Sales of Investments | 18.77M | 27.97M | 38.62M | 126.02M | 90.29M |
| Other Investing Activities | (2.61M) | (1.37M) | 1.39M | (4.12M) | (6.61M) |
| Investing Cash Flow | (28.67M) | (32.78M) | (649.12M) | (124.93M) | (70.33M) |
| Debt Repayment | 32.1M | (1.78M) | 526.34M | 10.17M | 5.99M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 2.86M |
| Common Stock Repurchased | (28.87M) | (39.91M) | (58.14M) | (85.46M) | (75.59M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (40.24M) | 15.25M | (14.11M) | (5.67M) | (687K) |
| Financing Cash Flow | (37.02M) | (26.44M) | 454.09M | (80.95M) | (67.43M) |
| Effect of Forex Changes | (223K) | (220K) | (282K) | (190K) | 210K |
| Net Change in Cash | 32.08M | 29.75M | (11.8M) | 7.31M | 18.57M |
| Free Cash Flow | 70.54M | 65.15M | 145.34M | 172.35M | 121.23M |
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
Intrinsic Alpha fair value
Locked
Current Price
$29.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.